Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Office Of Criminal Investigations May Undergo Overhaul With The Resignation of Its Director

This article was originally published in The Pink Sheet Daily

Executive Summary

Terry Vermillion, who has headed up the office for 18 years, resigned two months after a whistleblower complaint about him was made public.

You may also be interested in...



FDA Investigators Search For Silver Bullets In Off-Label Probes

OCI Director John Roth set to depart upon his confirmation to Homeland Security Department post.

FDA's New ORA Head, Dara Corrigan, Has Broad Enforcement Experience

Former acting HHS inspector general will become associate commissioner for regulatory affairs two years after Margaret O'Keeffe Glavin's retirement.

Hamburg Outlines Planned Reforms Of FDA Criminal Investigations Office

FDA Commissioner Margaret Hamburg outlined reforms planned for the agency's Office of Criminal Investigations, including new criteria for selecting misdemeanor prosecution cases against responsible corporate officials

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel